Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Respiratory SCE > COPD > Flashcards

COPD Flashcards

1
Q

What is the association with blood eosinophils and COPD?

A

Lower blood and sputum eosinophils are associated with a greater presence of proteobacteria, notably hemophilus, increased bacterial infection and pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the benefits of Phosphodiesterase 4 inhibitors in severe to very severe COPD and history of exacerbation?

A
  1. PDE4 inibitor improves lung function and reduces moderate and severe exacerbations
  2. PDE4 inhibitor improves lung function and decreases exacerbation in patients who are on a fixed dose LABA-ICS combinations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Are long term glucocorticoids useful in COPD ?

A

No. No evidence of benefits and numerous side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Independent of ICS use at what blood eosinophil count is there an increased risk of pneumonia ?

A

Blood Eosinophil count <2%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Who is at increased risk of pneumonia on ICS ?

A

Current smoker
>55 years
History of prev pneumonia or exacerbation
BMI<25
Poor MRC grade
Severe airflow obstruction

Independent of ICS use , eosinophils <2% assoc w pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

As per GOLD criteria what factors STRONGLY favour adding ICS to LABA?

A
  • Hx of hospitalization for exacerbations of COPD
  • > / 2 moderate exacerbations per year
  • Blood eosinophils >300 cells /ul
  • Hx of concomitant asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

As per GOLD criteria what factors favour adding ICS to LABA?

A

1 moderate exacerbation of COPD per year (despite appropriate LABA maintenance therapy)
Blood eos 100-300 cells /ul

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

As per GOLD criteria what factors are AGAINST adding ICS to LABA?

A
  • Repeated pneumonia events
  • Blood eos <100 cells /ul
  • History of mycobacterium infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Implications of acute glucocorticoids ?

A

Reduced rate of treatment failure
Reduced rate of relapse
Improve lung function
Improve breathlessness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hoe do PDE4 inhibitors work?

A

Reduce inflammation by inhibiting the breakdown of intracellula cyclic AMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is Roflumilast?

A

Roflumilast is a phosphodiesterase 4 inhibitor. It is an oral medication take. Once a day with no direct bronchodilator activity.

It reduces moderate and severe exacerbations requiring treatment with systemic corticosteroids in patients with :
- chronic bronchitis
- severe to very severe COPD
- hx of exacerbations

Its effects on lung functions are seen when added to LABA or LABA-ICS

The beneficial effects of Roflumilast increase in patients with prior history of hospitalisations

** NB no study directly comparing Roflumilast with ICS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the side effects of Roflumilast?

A

Diarrhoea
Nausea
Weight loss (around 2kg in trial)
Abdo pain
Sleep disturbance
Headache

Adverse effects seem to occur early in treatment and reduce over time with continued treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Who should you avoid Roflumilast in?

A
  • Underweight patients
  • Depressed patients (caution)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the prophylactic abx used in COPD?

A

Azithromycin 250mg / day OR Azithromycin 500mg three times a week

OR

Erythromycin 250mg BD

Over one year in patients prone to exacerbations , the above have been shown to reduce risk of exacerbations compared with usual care (no data beyond one year)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the therapeutic interventions proven to reduce COPD mortality ?

A

LABA + LAMA + ICS
Smoking Cessation
Pulmonary Rehabilitation
LTOT
NIV
LVRS (Upper lobe predominant emphysema with low exercise capacity) / Lung transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the benefits of PR?

A

Pulmonary Rehabilitation improves :
- Dyspnoea
- Health Status
- Exercise tolerance
In stable patients

PR reduces hospitalisation among patients who have had a recent exacerbations (<4 weeks from prior hospitatlisation)

PR leads to a reduction in symptoms of anxiety and depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Is educations and self management helpful in COPD?

A
  • Education alone has not been shown to be effective
  • Self management intervention with communication with a health care professional improves health status and decreases hospitalisation and emergency department visits
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Is integrated care programs useful in COPD?

A

Integrative care and telehealth have no demonstrated benefits at this time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is pulmonary rehabilitation ?

A

Pulmonary rehabilitation is defined as “a comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, self-management intervention aiming at behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the aim of PR?

A

Offer to COPD patients with view to improving exercise capacity by clinically important amount as well as dyspnoea. Resistance can affect quadriceps strength. PR should improve psychological wellbeing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the caveats to PR referral?

A

If AAA >5.5cm need to review, if not fit for surgery can still attend PR and undertake moderate intensity aerobic exercise but must not include resistance

If severe locomotor dysfunction ie with PVD should not be referred

If significant cognitive impairment should not be referred

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the MRC cut offs for PR referral ?

A

MRC 3-5

Or

Can be MRC 2 if functionally limited by breathlessness

(MRC 5 and housebound can be difficult as can’t routinely offer home PR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

How is PR set up?

A

Twice weekly sessions for 6-12 weeks, patients should attend minimum of 12 recommended

Cohort or rolling is fine

Undertake aerobic training and muscle resistance . Generic exercises which are individualised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

When should patients be offered PR following discharge with exacerbation?

A

PR should commence within 1 month of discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What other resp conditions can PR be utilised for ?

A

Non CF Bronchiectasis
ILD

NB Asthma not routinely recommended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

When can you repeat PR?

A

Can repeat PR if done >1 year previously but note if didn’t get benefit last time unlikely they will this time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Who should get Roflumilast?

A
  • FEV1 <50% predicted
  • 2 or more exacerbations in the last 12 months despite triple therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What does evidence show is the effect of Roflumilast?

A

Reduced rate of moderate or severe exacerbation compared with placebo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is the most common complication following LVRS?

A

Persistent air leak

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the aim of endobronchial valve insertion?

A

To reduce the lung volume in emphysema to achieve atelectasis of selected lung segments

It is done by delivering a catheter passed along a bronchoscope, a synthetic valve is placed in the target location and fixed to the bronchial wall. Valve is designed to prevent airflow in inspiration but allow air and mucus out during expiration

Several valves may be needed (1 or more for each segment to be treated)

Duckbill and umbrella valves ; duckbill in circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

In the right patients what is the effect of LVRS/EBV?

A
  • Reduction in gas trapping - improving lung function and reducing sensation of breathlessness
  • Improving exercise capacity
  • Improving QOL
  • Prolonging survival by delaying development of resp failure and need for frequent hospitalization
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What is the only intervention that modifiers the natural history of COPD?

A

Stopping smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

What is the benefit for LVRS via VATS?

A

Improves QOL
Improves exercise capacity
Improves lung function

Of those with severe emphysema in the short term
NB hospital stay with VATs is shorter than open

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What is the benefit of LVR by EBV?

A

Improves QOL
Improves exercise capacity
Improves lung function

*Greatest for those with heterogenous emphysema without collateral ventilation and those where lobar occlusion is complete

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What is the benefit of LVR via open surgery?

A

Improves QOL
Improves exercise capacity
Improves lung function

Sustained improvement with QOL and exercise capacity demonstrated

Those with UL emphysema and reduced exercise capacity will benefit most

36
Q

What are the criteria for LVR MDT discussion?

A
  1. Evidence of symptomatic hyperinflation due to emphysema with impaired QOL. MRC > 3
  2. PR within 12 months or ongoing participation
  3. Non smoker for at least 4 months
  4. 6MWT >140m or ISWT >80m
  5. FEV1 <50%
  6. RV >150%
  7. RV /TLC > 55%
  8. DLCO >20%
  9. PCO2 < 7
  10. BMI > 18

NB not suitable if severe co-morbidities , severe progressive disease, severe PH

37
Q

What are the main reasons LVR found not to be appropriate following MDT discussion?

A

Lack of suitable target area
XS risk (BMI/DLCO)
Significant co-morbidities

38
Q

What are the criteria for LVRS following MDT discussion?

A

1.Upper lobe heterogenous emphysema
2. RV/TLC >60 , TLCO >20 , BMI>18
3. Collateral ventilation and low exercise capacity
4. Predominantly apical disease with collateral ventilation and reduced exercise capacity
5. Lower lobe heterogenous disease with collateral ventilation

39
Q

What are the criteria for EBV following MDT discussion?

A
  1. Upper lobe or lower lobe heterogenous emphysema without collateral ventilation
  2. RV >180% , TLCO > 20 , BMI > 18
  3. Previous thoracic surgery
40
Q

What is included in the DECAF score ?

A

Dyspnoea (0: can leave house , 1: can’t leave house but can wash dress , 2: can’t wash /dress/ leave house

Eosinophilia (<0.5)

Consolidation (Yes)

Acidaemia (pH <7.3)

aF (Yes)

41
Q

What does DECAF score predict?

A

In hospital mortality in acute COPD exacerbation

42
Q

If patient has DECAF score of 1 what is their hospital mortality ?

A

1.5%

Score of 0-1 , low risk 0-1.5%

43
Q

If patient has DECAF score of 2 what is their hospital mortality ?

A

5.4%

44
Q

If patient has DECAF score of 3-6 what is their hospital mortality ?

A

15.3-50%

HIGH risk

45
Q

What is the BODE score and what does it consist of ?

A

Predicts 4 year survival in COPD patients

BMI (<21)
Obstructive Spirometry (FEV1)
Dyspnoea
Exercise (6MWT)

46
Q

What is the associated 4 year survival with BODE 0-2?

A

80%

47
Q

What is the associated 4 year survival with BODE 3-4?

A

67%

48
Q

What is the associated 4 year survival with BODE 5-6?

A

57%

49
Q

What is the associated 4 year survival with BODE 7-10?

A

18%

50
Q

What is the CAT tool ?

A

COPD Assessment tool, identifies overall impact of COPD on patients healthy

51
Q

What does the CAT tool include ?

A

Cough, Phlegm, Chest tightness , Breathlessness, Activities , Confidence , Sleep , Energy

52
Q

What does a CAT score of 0-10 indicate ?

A

Low health impact

53
Q

What does a CAT score of 11-20 indicate ?

A

Medium health impact

54
Q

What does a CAT score of 21-30 indicate ?

A

High health impact

55
Q

What does a CAT score of 31-40 indicate ?

A

V. High health impact

56
Q

Outline MRC 1 (mMRC 0)

A

Not troubled by breathlessness except with strenuous exercise

57
Q

Outline MRC 2 (mMRC 1)

A

SOB when hurrying or walking up a slight hill

58
Q

Outline MRC 3 (mMRC 2)

A

Walks slower than contemporaries on level ground bc of breathlessness or has to stop for breath when walking at own pace

59
Q

Outline MRC 4 (mMRC 3)

A

Stops for breath after walking around 100m after a few minutes on level ground

60
Q

Outline MRC5 (mMRC 4)

A

Too breathless to leave the house or breathless when washing /dressing

61
Q

What is independent risk factor for cancer on CT?

A

Emphysema

62
Q

As per NICE what ix should all COPD patients have?

A

Spirometry, FBC, CXR , BMI

(Can also consider Sputum, serial peak flow , ECG, Echo, CT scan)

63
Q

What are the classifications for COPD as per NICE/BTS?

A

All with FEV1/FVC <0.7

MILD FEV1 ≥ 80%
MODERATE 50-80%
SEVERE 30-50%
VERY SEVERE <30% (or severe with respiratory failure)

64
Q

What are the fundamentals of COPD care ?

A
  • Support to stop smoking
  • Offer pneumococcal , COVID and flu vaccines
  • Offer PR if indicated
  • Co develop personalised Mx plan
  • Optimise treatment

Inhaled therapies only if the above optimised

65
Q

What are the treatment algorithms inhaler wise as per NICE?

A

SABA or SAMA as first line

If limited by symptoms / exacerbation despite tx

-IF no asthmatic features suggesting steroid responsiveness : LABA/LAMA BUT if continued to have day to day sx affecting life LABA-LAMA-ICS or if 1 severe or 2 moderate exacerbations LABA-LAMA-ICS

  • IF asthmatic features (ie prev asthma , atopy, high eosinophil count , variation in FEV1 , diurnal variation) : LABA/ICS BUT if still day to day symptoms or 1 significant or 2 moderate exacerbations then LABA-LAMA-ICS
66
Q

Who should have steroid in COPD?

A

Long term corticosteroids not recommended , if unavoidable aim to reduce as much as possible

If over 65 years then should have prophylaxis

67
Q

Who should have theophylline ?

A

Only after trial of SABA/ LABA etc or in people who are unable to tolerate inhaled therapy. Difficult pharmacokinetics in the elderly

Reduce dose of theophylline for people who having exacerbation if prescribed macrolide (clari) or fluoroquinolone (Ciprofloxacin)

68
Q

What are the criteria for prophylactic Azithromycin?

A

Patients need to :
- non smoker
- optimised non pharmacological and inhaled therapies , relevant vaccinations and continue to have one or more of following :

—- frequent (typical ≥ 4 or more per year) exacerbations with sputum production
—- prolonged exacerbations with sputum production
—- exacerbations resulting in hospitalization

BEFORE offering, ensure:
- Sputum culture and sensitivity and TB done - to identify a specific cases of persistent infection or recurrent infection that may need tx (NTM , Pseud)
- Training in sputum clearance
- CT throrax to rule out bronchiectasis

Also:
ECG (to review QTc)
LFTs
Warn we small risk of hearing loss and tinnitus

Review @ 3/12 and then 6/12

** NOT necessary to stop prophylactic Azithro in exacerbation **

69
Q

How do we assess for LTOT?

A

2 ABGs on 3 occasions at least 3 weeks apart

70
Q

What are the criteria for LTOT?

A

PaO2 <7.3

Or PaO2 7.3 - 8 with:
- peripheral oedema
- pulmonary HTN
- secondary polycythemia

71
Q

Who is not allowed LTOT?

A

Smokers (need to have quit for 6 months)

72
Q

Who gets referred for Bullectomy?

A

Breathless and CT scan shows bullae occupying at least 1/3

73
Q

In what gene is the mutation that leads to alpha 1 antitrypsin deficiency ?

A

SERPINA 1 gene

74
Q

What is PRISM?

A

Preserved Ratio Spirometry

Some patients can have respiratory sx and /or emphysema on CT or physiological abnormalities (including low or normal FEV1, gas trapping, hyperinflation, reduced lung diffusion capacity and /or rapid FEV1 decline) without airflow obstruction

At risk of developing airflow obstruction but not all do

75
Q

Why do COPD patients sometimes collapse after coughing ?

A

Syncope during coughing in patients with severe COPD can occur due to rapid increase in the intrathoracic pressure during prolonged coughing attacks (NB can also cause rib #)

76
Q

What is GOLD A?

A

0-1 moderate exacerbations (not req hospitalization)
mMRC 0-1
CAT <10

77
Q

What is GOLD B?

A

0-1 moderate exacerbations (not req hospitalization)
mMRC ≥ 2
CAT ≥ 10

78
Q

What is GOLD E?

A

2 moderate exacerbations or ≥ 1 leading to hospitalization

79
Q

What proportion of patients continue to smoke despite having COPD dx as per GOLD estimation?

A

40%

80
Q

What are the effects of bronchodilator therapy ?

A

LABA and LAMAs improve:
- lung function
- dyspnoea
- health status
- reduce exacerbation rates

LAMAs have a greater reduction of exacerbation compared with LABAs and decrease hospitalisations

Combined LABA/LAMA therapy improves FEV1 and reduces symptoms compared with mono therapy

81
Q

Treatment for Group A GOLD pts ?

A

SABA/SAMA

82
Q

Treatment for Group B GOLD pts ?

A

LABA and LAMA

83
Q

Treatment for Group E GOLD pts ?

A

LABA and LAMA (and ICS if eos ≥ 0.3)

84
Q

How long does it take to recover from COPD exacerbation?

A

4-6 weeks ; some never recover to baseline

85
Q

Who should get annual LDCT scans ?

A

Ppl w COPD due to smoking

86
Q

How do you calculate pack years

A

No. Of cigarettes per day/20 * Years

Respiratory SCE (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions